This was the stock's second consecutive day of losses.
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback